First patient dosed in second Phase 2 add-on Ketamine Trial in Treatment-Resistant Depression (TRD)
June 08, 2022 08:20 ET
|
HMNC Holding GmbH
Dosing has commenced in HMNC Brain Health and Develco Pharma’s Phase 2 oral prolonged-release Ketamine (KET01) Study The trial will assess the efficacy, safety, and tolerability of add-on treatment...
HMNC Brain Health to Participate in Upcoming Investor Conferences in April 2022
April 11, 2022 08:00 ET
|
HMNC Holding GmbH
MUNICH, Germany, April 11, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a global precision psychiatry biopharma company, pioneering the development of personalized therapies...
HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-Resistant Depression (TRD), suggesting antidepressant efficacy and showing Placebo-Level Dissociative Side Effects in Phase 2 oral prolonged-release Ketamine (KET01) Study
March 31, 2022 08:30 ET
|
HMNC Holding GmbH
Phase 2 Proof-of-Concept study in TRD patients resistant to standard antidepressants suggests positive trend in efficacy.Potential first-in-class oral prolonged-release formulation of ketamine, KET01,...
HMNC Brain Health Appoints Dr. Bertram Müller-Myhsok as Head of Precision Psychiatry
February 24, 2022 08:30 ET
|
HMNC Holding GmbH
Appointment accelerates Company’s development roadmap in targeted therapies for neuropsychiatric disorders The Head of the Statistical Genetics Research Group at Max-Planck-Institute of Psychiatry in...
HMNC Brain Health Expands International Patent Portfolio with Two Stress-axis Related Substances for Major Depressive Disorder
January 25, 2022 08:30 ET
|
HMNC Holding GmbH
In-Licensing arrangement with the renowned Max Planck Society, extends patent protection for clinical research and strengthens Nelivabon and Cortibon developmental projects The Company has also...
HMNC Brain Health to Participate in H.C. Wainwright Bioconnect Conference in January 2022
January 06, 2022 08:54 ET
|
HMNC Holding GmbH
MUNICH, Germany, Jan. 06, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “Company”), a clinical stage precision psychiatry biopharma company, pioneering the development of personalized...
HMNC Brain Health Names Nir Naor New Chief Financial Officer
December 14, 2021 08:30 ET
|
HMNC Holding GmbH
--Appointment strengthens Company’s global management team, brings vast capital market expertise, unique network in the global financial community, and robust operational industry experience-- ...
HMNC Brain Health to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference
December 01, 2021 10:37 ET
|
HMNC Holding GmbH
MUNICH, Germany, Dec. 01, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies powered by...
HMNC Brain Health to Participate in Microdose’s Wonderland: Miami Conference on November 8-9, 2021
November 02, 2021 08:30 ET
|
HMNC Holding GmbH
MUNICH, Germany, Nov. 02, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies powered by...
HMNC Brain Health Appoints Head of Regulatory Affairs
November 01, 2021 08:30 ET
|
HMNC Holding GmbH
MUNICH, Nov. 01, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health ("HMNC" or the "company"), a clinical-stage biopharma company pioneering the development of personalized therapies powered by predictive...